Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00465725 · ClinicalTrials.gov registry record · Phase 1

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Poniard Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
3
Study locations

NCT00465725: Completed Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Poniard Pharmaceuticals.

NCT00465725 is a Phase 1 study of Breast Cancer and Prostate Cancer that has completed, run by Poniard Pharmaceuticals. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00465725, a Phase 1 study of Breast Cancer and Prostate Cancer, has completed, sponsored by Poniard Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
3
Study locations

Study Summary

Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve after treatment with chemotherapy. In these studies, picoplatin was administered intravenously. A capsule containing picoplatin has been formulated. This study will investigate the activity of the oral capsule in humans. Participants with advanced solid tumors will be enrolled.

Interventions

  • DRUG Picoplatin

Study Locations (3)

Georgia

  • Georgia Cancer Specialists - Atlanta

Nevada

  • Nevada Cancer Institute - Las Vegas

Washington

  • Northwest Medical Specialties - Tacoma

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2007-04
Est. Completion 2009-07
Phase Phase 1
Poniard Pharmaceuticals

4 total trials

What the finished NCT00465725 record still lists

NCT00465725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Picoplatin is the first listed.

NCT00465725 reports a single indexed study location in Georgia, Nevada, Washington.

Frequently Asked Questions

What is clinical trial NCT00465725 about?

NCT00465725 is a clinical study titled "A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors". Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve after treatment with chemotherapy. In these studies, picoplatin was admini...

What is the current status of trial NCT00465725?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-04. Estimated completion is 2009-07.

What conditions does trial NCT00465725 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer.

What interventions are being tested in trial NCT00465725?

The interventions under investigation include: Picoplatin (DRUG).

Who is sponsoring clinical trial NCT00465725?

This trial is sponsored by Poniard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00465725 being conducted?

This trial has 3 study locations across Georgia, Nevada, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00465725's enrollment target sits among peer trials

18 1118th of 1224 higher than 97 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00465725, the US trial registry maintained by the National Library of Medicine. NCT00465725 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.